Andy Palmer

Clinicians want to use AI but don’t have the bandwidth to evaluate all the different models. Meet Health Olymp, an AI tool purpose-built for clinicians. Here’s why this matters 👇 1. Health and life science experts gain instant access to frontier models for free. No procurement hoops or IT bottlenecks. Every clinician gets their own sandbox to explore. 2. Clinicians can compare models side by side and pick the one that works best for their use case. That transparency builds trust and sparks ideas for novel AI applications in care delivery, diagnostics, and research. 3. Most AI benchmarks are too generic or disconnected from clinical reality. Health Olymp brings frontline feedback into the loop, helping the industry identify models that perform reliably in real world clinical environments. Congrats to Ruslan Nazarenko and the Lumos team as they put AI model benchmarking directly into the hands of healthcare professionals. ⬇️ (link in comments)

148

53 Comments

This is really worth catching, with Anna Codina outlining the view of SciY on the role of #labdigitalization to support #labautomation and accelerate R&D ZONTAL Mestrelab Research S.L. #SynTQ

21

1 Comment

Distribution is becoming the moat in healthcare AI Anthropic’s recent Claude for Healthcare update was a good example: the main features were not focused on model performance, it was connectivity, making Claude usable inside the healthcare enterprise stack. The main drops were: -> Coverage rules (CMS Coverage Database connector): check whether a treatment is reimbursable and under what conditions -> Coding (ICD-10 connector): translate clinical language into billing/diagnosis codes -> Provider verification (NPI Registry connector): validate provider identity for credentialing and claims -> Prior Authorization Agent: assemble documentation and rationale for approvals/appeals -> Interoperability tooling: make it easier to plug into health IT systems This shift creates real opportunity for founders. Healthcare is fragmented by country, system, and workflow, so teams that can embed applications deeply in specific workflows can build meaningful markets, even from narrow starting points. Source: https://lnkd.in/dFEi8UDP

12

2 Comments

Excited to spotlight Anna Marie Wagner and our AI Biohub initiative! Anna Marie breaks down why AI-native biotech startups need specialized support—and how we’re building that ecosystem. Plus, catch her on The Dish podcast sharing insights on early AI adoption in biotech and leading multidisciplinary teams. C10 Labs

26

DCVC company Valar Labs is demonstrably increasing survival time and quality of life for cancer patients, including pancreatic cancer patients

20

Love this Andrei Georgescu, Ph.D. “Success, to me, looks like Vivodyne becoming the modern infrastructure for drug programs that seek to eradicate the extremely burdensome diseases of today, like fibrosis, cancers, inflammatory disease, autoimmunity... I see Vivodyne as the fundamental infrastructure needed to drive successful new therapies for such complex diseases that human trial-and-error cannot solve quickly enough.”

4